TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04301635

Intervention type: PROCEDURE
Intervention: Maxillo-mandibular Advancement + Counterclockwise rotation
Description: Maxilla: Lefort I osteotomy Mandible: Obwegeser-Dal-Pont osteotomy Movements: Advance and counterclockwise rotation

Intervention type: PROCEDURE
Intervention: Maxillo-mandibular Advancement + Counterclockwise rotation
Description: Maxilla: Lefort I osteotomy Mandible: Obwegeser-Dal-Pont osteotomy Movements: Advance and counterclockwise rotation
Study: NCT02299375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losmapimod tablets
Description: Losmapimod tablets will be provided as 15 mg strength in a formulation containing lactose. Administered orally, twice daily approximately 12 hours apart and with food and water for the duration of the treatment period. Participants will be instructed to take their medication with a full glass of water twice-daily within 30 minutes after meals for the duration of their treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablets
Description: Placebo tablets will be provided in a formulation containing lactose and visually matching the losmapimod tablets. Administered orally, twice daily approximately 12 hours apart and with food and water for the duration of the treatment period. Participants will be instructed to take their medication with a full glass of water twice-daily within 30 minutes after meals for the duration of their treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol MDI
Description: Salbutamol MDI will be provided as a rescue medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol MDI
Description: Salbutamol MDI will be provided as a rescue medication.
Study: NCT02550691

Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood sampling
Description: A blood sample will be taken on subject carrying specific genotype

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood sampling
Description: A blood sample will be taken on subject carrying specific genotype

Intervention type: PROCEDURE
Group type: OTHER
Intervention: blood sampling
Description: A blood sample will be taken on subject carrying specific genotype
Study: NCT01294033

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fractional inspired oxygen (FiO2) 0.21

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fractional inspired oxygen 0.28
Description: Supplemental oxygen
Study: NCT00704184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Vaniprevir
Description: Vaniprevir 300 mg b.i.d., 600 mg b.i.d., 600 mg q.d., or 800 mg q.d.; duration of treatment: 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Vaniprevir
Description: Vaniprevir 300 mg b.i.d., 600 mg b.i.d., 600 mg q.d., or 800 mg q.d.; duration of treatment: 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Vaniprevir
Description: Vaniprevir 300 mg b.i.d., 600 mg b.i.d., 600 mg q.d., or 800 mg q.d.; duration of treatment: 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Vaniprevir
Description: Vaniprevir 300 mg b.i.d., 600 mg b.i.d., 600 mg q.d., or 800 mg q.d.; duration of treatment: 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Pegylated-Interferon (Peg-IFN)
Description: Peg-IFN 180 mcg once-weekly subcutaneous injection; duration of treatment: 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Pegylated-Interferon (Peg-IFN)
Description: Peg-IFN 180 mcg once-weekly subcutaneous injection; duration of treatment: 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Pegylated-Interferon (Peg-IFN)
Description: Peg-IFN 180 mcg once-weekly subcutaneous injection; duration of treatment: 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Pegylated-Interferon (Peg-IFN)
Description: Peg-IFN 180 mcg once-weekly subcutaneous injection; duration of treatment: 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Pegylated-Interferon (Peg-IFN)
Description: Peg-IFN 180 mcg once-weekly subcutaneous injection; duration of treatment: 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Ribavirin
Description: Ribavirin 200 mg tablet b.i.d. (dose based on body weight); duration of treatment: 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Ribavirin
Description: Ribavirin 200 mg tablet b.i.d. (dose based on body weight); duration of treatment: 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Ribavirin
Description: Ribavirin 200 mg tablet b.i.d. (dose based on body weight); duration of treatment: 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Ribavirin
Description: Ribavirin 200 mg tablet b.i.d. (dose based on body weight); duration of treatment: 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Ribavirin
Description: Ribavirin 200 mg tablet b.i.d. (dose based on body weight); duration of treatment: 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: placebo
Description: Matching placebo to vaniprevir; duration of treatment: 28 days
Study: NCT02058017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPB-51602
Study: NCT00247208

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taxus polymer-based paclitaxel-eluting stent
Description: Two different types of stents (paclitaxel-eluting and a similar bare metal stent) are being compared in saphenous vein graft lesions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Express 2 bare metal stent
Description: Two different types of stents (paclitaxel-eluting and a similar bare metal stent) are being compared in saphenous vein graft lesions.
Study: NCT04125810

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Probiotic

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02539225

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramucirumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-1
Description: Administered PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Administered PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered IV
Study: NCT00111085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clazosentan 1 mg/h
Description: Subjects receive intravenous clazosentan at a rate of 1 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clazosentan 5 mg/h
Description: Subjects receive intravenous clazosentan at a rate of 5 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clazosentan 15 mg/h
Description: Subjects receive intravenous clazosentan at a rate of 15 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive intravenous placebo starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
Study: NCT00765271

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abacavir
Description: Group 1 will be instructed to take • Abacavir 600 mg once daily (two 300 mg tablets once daily) as part of regular treatment throughout the whole study~Group 2 will be instructed to take~• Abacavir 600 mg once daily (two 300 mg tablets once daily) as part of regular treatment throughout the whole study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abacavir
Description: Group 1 will be instructed to take • Abacavir 600 mg once daily (two 300 mg tablets once daily) as part of regular treatment throughout the whole study~Group 2 will be instructed to take~• Abacavir 600 mg once daily (two 300 mg tablets once daily) as part of regular treatment throughout the whole study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir/ritonavir
Description: Group 1 will be instructed to take~• Three 300mg Darunavir tablets and one 100mg ritonavir tablet once a day for 14 days (on days 2 - 15)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: Group 1 will be instructed to take • Two 200mg Raltegravir tablets twice daily for 14 days (on 16 - 29)~Group 2 will be instructed to take~• Two 200mg Raltegravir tablets twice daily for 14 days (on days 2-15)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: Group 1 will be instructed to take • Two 200mg Raltegravir tablets twice daily for 14 days (on 16 - 29)~Group 2 will be instructed to take~• Two 200mg Raltegravir tablets twice daily for 14 days (on days 2-15)
Study: NCT01735019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of remifentanil with TCI system
Description: A given effect site concentration of remifentanil would be administered to subjects using TCI system. According to biased coin design, the given concentration of remifentanil is determined according to success or failure of just previously enrolled patient. If the former patient did not cough during anesthetic emergence at a given concentration (success), the next patient will be randomly allocated into the same concentration of remifentanil with 18/19 of probability or the lower concentration of remifentanil by 0.4 ng/ml with 1/19 of probability. If the former patient coughed during anesthetic emergence (failure), the next will be automatically allocated into the higher concentration of remifentanil by 0.4 ng/ml.
Study: NCT01115959

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valproic acid
Description: treatment of 1 month dosage of 400 mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo bid
Study: NCT02309034

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jump exercise
Description: Land Group / Jump (LG): Will hold weekly classes of nutritional guidance and three weekly sessions of jump, for 12 weeks, divided into warm up, main aerobics and relaxation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aquatic exercise
Description: Group Water / Water aerobics (WG): Will hold weekly classes of nutritional guidance and three weekly sessions of water, for 12 weeks, divided into warm up, main aerobics and relaxation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional guidance
Description: Control Group (CG): take part only of weekly classes of nutritional guidance, in addition to a closed group on Facebook in order to encourage them and increase attention to the group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional guidance
Description: Control Group (CG): take part only of weekly classes of nutritional guidance, in addition to a closed group on Facebook in order to encourage them and increase attention to the group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional guidance
Description: Control Group (CG): take part only of weekly classes of nutritional guidance, in addition to a closed group on Facebook in order to encourage them and increase attention to the group.
Study: NCT03473340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone Capsule
Description: Dosing:~Days 1 through 7, 267 mg three times daily; Days 8 through 14, 534 mg three times daily; Days 15 through end of treatment (24 weeks), 801 mg three times daily duration: 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: Dosing:~* Days 1 through 7, 267 mg three times daily;~* Days 8 through 14, 534 mg three times daily;~* Days 15 through end of treatment (24 weeks), 801 mg three times daily duration: 24 weeks
Study: NCT00096915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin Alfa
Description: QM administration for 32 weeks, allowable doses:~15, 20, 30, 40, 50, 60, 80, 100, 150, 200, 300, 400, 500, 600 and 800 mcg
Study: NCT00593697

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab (9 weeks) + docetaxel
Description: Patients diagnosed with early breast cancer with a high risk of disease recurrence will be randomly allocated to one of the following 2 arms in a 1:1 ratio:~A. Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -\> 3-weekly FE75C (3 cycles) (HT x3 -\>FE75C x3) B. Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -\> 3-weekly FE75C (3 cycles) -\> trastuzumab to complete 1 year (14 3-weekly infusions) (HT x3 -\>FE75C x3 -\> H3wkly x14)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab (9 weeks) + docetaxel + CEF + trastuzumab (up to 51 weeks)
Description: Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -\> 3-weekly FE75C (3 cycles) -\> trastuzumab to complete 1 year (14 3-weekly infusions) (HT x3 -\>FE75C x3 -\> H3wkly x14)
Study: NCT03182010

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cesarean section incision closure using barbed sutures
Description: Cesarean section incision will be closed using a 24-cm × 24-cm 0 polydioxanone double-armed suture on a 26-mm half-circle reverse cutting needle( STRATAFIX™ Spiral PDO Knotless Tissue Control Device, Ethicon Inc , Somerville, NJ, USA ).Ultrasound examination will be performed 6 months after the operation to measure the residual myometrial thickness and the scar depth.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cesarean section incision closure using conventional sutures
Description: Cesarean section incision will be closed using 1-0 polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ) .Ultrasound examination will be performed 6 months after the operation to measure the residual myometrial thickness and the scar depth.
Study: NCT04756323

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: medium dosage inactivated SARS-CoV-2 vaccine
Description: medium dosage

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: medium dosage inactivated SARS-CoV-2 vaccine
Description: medium dosage

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: medium dosage inactivated SARS-CoV-2 vaccine
Description: medium dosage

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: medium dosage inactivated SARS-CoV-2 vaccine
Description: medium dosage

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: high dosage inactivated SARS-CoV-2 vaccine
Description: high dosage

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: high dosage inactivated SARS-CoV-2 vaccine
Description: high dosage

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: high dosage inactivated SARS-CoV-2 vaccine
Description: high dosage

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: high dosage inactivated SARS-CoV-2 vaccine
Description: high dosage

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT02678572

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Melphalan/HDS
Description: Melphalan (3 mg/kg IBW) with Hepatic Device System (HDS)
Study: NCT03843021

Intervention type: OTHER
Intervention: VAD Infection Prevention Survey
Description: Healthcare providers caring for VAD Therapy recipients will answer questions regarding processes of care at their institutions.
Study: NCT02531113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPC1063
Study: NCT00939978

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhEPO
Description: recombinant human erythropoietin(rhEPO)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rhEPO
Description: recombinant human erythropoietin(rhEPO)
Study: NCT03680417

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles-Rubella (MR) Vaccine
Description: Measles and Rubella Vaccine, live attenuated (Serum Institute of India) Form : Freeze dried Dose : 1 dose 0.5 ml contains not less than 1000 CCID50 of measles virus and 1000 CCID50 of rubella virus.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles-Rubella (MR) Vaccine
Description: Measles and Rubella Vaccine, live attenuated (Serum Institute of India) Form : Freeze dried Dose : 1 dose 0.5 ml contains not less than 1000 CCID50 of measles virus and 1000 CCID50 of rubella virus.
Study: NCT03857958

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic retrograde cholangio-pancreatography
Description: In patients who were identified to have malignant hilar biliary obstruction, bilateral stents insertion is attempted via ERCP. There will be two groups divided by stent material; FCSEMS and Plastic stent.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic retrograde cholangio-pancreatography
Description: In patients who were identified to have malignant hilar biliary obstruction, bilateral stents insertion is attempted via ERCP. There will be two groups divided by stent material; FCSEMS and Plastic stent.
Study: NCT04164355

Intervention type: DRUG
Intervention: Tadalafil 20 MG
Description: To study retinal and choriocapillary features in patients undergoing Tadalafil 20 mg orally, on alternate days, at baseline and 1, 3, 6 months after radical prostatectomy
Study: NCT03928496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA
Description: Subjects were injected with 0.1 ml (12.5 units of Abobotulinumtoxina) into 31 distinct muscle locations in the head and neck

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Subjects were injected with 0.1 ml of preservative free normal saline into 31 distinct muscle locations in the head and neck
Study: NCT01158157

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: ACAM2000
Description: Percutaneous administration of a droplet (2.5µg) of ACAM2000 using a bifurcated needle.
Study: NCT02298608

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nano Knife
Description: Percutaneous, CT guided, ablation of renal mass
Study: NCT01826188

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: THC 5mg/ml and CBS 50mg/ml
Description: olive oil containing THC and CBD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: olive oil without cannabis
Study: NCT00332163

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Administered by intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Recommended dosage regimen and administration of irinotecan was based on local standard of care, the package insert, and institutional guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Recommended dosage regimen and administration of irinotecan was based on local standard of care, the package insert, and institutional guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Chemotherapy consisting of irinotecan with infusional 5-fluorouracil and leucovorin. Recommended dosage regimen and administration of FOLFIRI was based on local standard of care, the package insert for each product, and institutional guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Chemotherapy consisting of irinotecan with infusional 5-fluorouracil and leucovorin. Recommended dosage regimen and administration of FOLFIRI was based on local standard of care, the package insert for each product, and institutional guidelines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pre-emptive Skin Treatment
Description: Pre-emptive skin treatment included a skin moisturizer (eg, Lubriderm), sunscreen (free of paraaminobenzoic acid (PABA), skin protection factor (SPF) 15 or higher, ultraviolet-A (UV-A), and UV-B protection), topical steroid (1% hydrocortisone cream) and oral antibiotic (doxycycline, 100 mg twice daily).
Study: NCT04293562

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study: NCT00332163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reactive Skin Treatment
Description: Treatment was based on symptoms and severity and may have included an emollient (eg, Lubriderm, Vaseline), sunscreen (SPF ≥ 15), oral antibiotic (eg, doxycycline, ciprofloxacin, cefadroxil, amoxicillin/clavulanic acid), topical steroid (hydrocortisone cream), topical antibiotic (clindamycin), oral systemic steroid, topical medical treatment (eg, silver sulfadiazine, Silvadene), topical antihistamine or oral antihistamine (hydroxyzine)
Study: NCT02226146

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bertilimumab